Mirae Asset Global Etfs Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $56.2 Billion
- Q3 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 95,625 shares of ARQT stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95,625
Previous 66,236
44.37%
Holding current value
$2.39 Million
Previous $928,000
94.18%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ARQT
# of Institutions
254Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...